

Supporting information

A tumor-sensitive biological metal-organic complex for drug delivery and cancer therapy

Zelei Jiang,^a Tong Wang,^a Shuai Yuan,^a Mengfan Wang,^{*,a,b} Wei Qi,^{a,b,c}

Rongxin Su,^{a,b,c} Zhimin He^a



^a School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300350, P. R. China.

^b The Co-Innovation Centre of Chemistry and Chemical Engineering of Tianjin, Tianjin 300072, P. R. China.

^c Tianjin Key Laboratory of Membrane Science and Desalination Technology, Tianjin 300350, P. R. China.

Corresponding author E-mail: mwang@tju.edu.cn (M.W.).





Table S1. bioMOC-Fe(Cys) synthesized at different temperatures

Temperature (°C)	SEM/TEM ^a	Morphology	Average Size (nm)
40		nanorod	L=380 ± 7.8 W=60~100 ^b
60		amorphous cluster	1400 ± 15.5 ^c
80	N.D.	N.D.	N.D.
120	N.D.	N.D.	N.D.
150	N.D.	N.D.	N.D.

^a Scale bars = 200 nm. ^b Statistical analysis of TEM/SEM images, L: length, W: width.

^c Measured using DLS.

Table S2. bioMOC-Zr(Cys) synthesized at different temperatures

Temperature (°C)	SEM/TEM ^a	Morphology	Average Size (nm)
40		amorphous cluster	695 ± 9.8^b
60		amorphous cluster	689 ± 8.7^b
80		amorphous cluster	567 ± 4.5^b
120		amorphous cluster	301 ± 3.9^b
150	N.D.	N.D.	N.D.

^a Scale bars = 200 nm. ^b Measured using DLS.

Table S3. Comparison of the cumulative amount of drug released from some GSH-sensitive NDDSs

NDDSs	Cumulative release (%)		Release time (h)	Reference
	No GSH (pH 7.4)	10 mM GSH (pH 7.4)		
TTMOF	16.5	78.5	140	Wang <i>et al.</i> ^[1]
ZDOS NPs	17.5	38.5	48	Ren <i>et al.</i> ^[2]
Mn-SS/DOX@PDA-PEG	18.5	45.5	24	Zhao <i>et al.</i> ^[3]
MSN-ss-GHA	11.77	51.1	60	Chen <i>et al.</i> ^[4]
MOF-Zr(DTBA)	50	87.4	22	Lei <i>et al.</i> ^[5]
bioMOC-Zn(Cys)	8.25	83.3	48	This study

Table S4. Comparison of the cytotoxicity of MOF-based drug carriers

Carriers	Cells	Concentration ($\mu\text{g/mL}$)	Incubation time (h)	Cell viability (%)	Reference
ZJU-101	PC12	200	24	80.0	Yang <i>et al.</i> ^[6]
PCN-221	PC12	100	24	90.0	Lin <i>et al.</i> ^[7]
Fe-MIL-53-NH ₂ -FA-5-FAM	HASMC	200	24	84.5	Gao <i>et al.</i> ^[8]
	MGC-803	200	24	78.5	
ZIF-8	HeLa	100	48	83.5	Ren <i>et al.</i> ²
	MCF-7	100	48	82.5	
MOF-Zr(DTBA)	HeLa	200	24	70.5	Lei <i>et al.</i> ⁵
	MDA-MB-231	200	24	80.5	
bioMOC-Zn(Cys)	A549	200	24	97.7	This study
	BEAS-2B	200	24	93.9	




Figure S1. The DLS analysis of bioMOC-Zn(Cys) synthesized at different temperatures.




Figure S2. FTIR spectra of *L*-cystine and the bioMOC-Zn(Cys) nanocarrier synthesized at 150 °C.




Figure S3. Elemental mapping images of a bioMOC-Zn(Cys) nanoparticle.



Figure S4. Photographs of lyophilized bioMOC-Zn(Cys) and DOX@bioMOC-Zn(Cys) powders.




Figure S5. Hydrodynamic diameters of DOX@bioMOC-Zn(Cys) incubated in 20% FBS (A). Drug leakage from DOX@bioMOC-Zn(Cys) during 30 days of storage in deionized water at 4 °C (B).




Figure S6. (A) SEM image of a bioMOC-Zn(Lys) particle. Scale bar =200 nm. (B) PXRD analysis of bioMOC-Zn(Lys).




Figure S7. Drug release from DOX@bioMOC-Zn(Cys) in PBS at different pH values (A). Drug release from DOX@bioMOC-Zn(Cys) in PBS (pH 7.4 or pH 5.5) with and without GSH (B).




Figure S8. CLSM images of A549 cells after a 4 h incubation with DOX@bioMOC-Zn(Cys). (A) Red fluorescence of DOX, (B) cell nuclei stained with DAPI, (C) late endosomes and lysosomes stained with LysoTracker Green and (D) merged image (scale bars: 10 μ m)

Confocal laser scanning microscopy (CLSM) analyses were used to investigate the endocytosis of DOX@bioMOC-Zn(Cys) in human lung cancer cells (A549 cells). The intrinsic red fluorescence of DOX was used to monitor the intracellular distribution of DOX@bioMOC-Zn(Cys). The blue fluorescence indicated the cell nuclei stained with DAPI. Late endosomes and lysosomes were stained with LysoTracker Green. As shown in **Figure S8**, the red fluorescence overlapped with both the green (endosomes and lysosomes) and blue areas (nuclei) in cells that had been exposed to DOX@bioMOC-Zn(Cys) for 4 h. Thus, DOX@bioMOC-Zn(Cys) was taken up by A549 cells via endocytosis, and the drug that accumulated in endosome/lysosomal compartments was further delivered to the cell nucleus.




Figure S9. Flow cytometry analysis of A549 cells (A) and BEAS-2B cells (B) after a 0.5-h treatment with free DOX (cyan), DOX@bioMOC-Zn(Cys) (orange) or the blank (black).

REFERENCES

- 1 X. Wang, Z. Dong, H. Cheng, S. Wan, W. Chen, M. Zou, J. Huo, H. Deng and X. Zhang, *Nanoscale*, 2015, **7**, 16061.
- 2 S. Z. Ren, D. Zhu, X. H. Zhu, B. Wang, Y. S. Yang, W. X. Sun, X. M. Wang, P. C. Lv, Z. C. Wang and H. L. Zhu, *ACS Appl. Mater. Interfaces*, 2019, **11**, 20678-20688.
- 3 J. Zhao, Y. Yang, X. Han, C. Liang, J. Liu, X. Song, Z. Ge and Z. Liu, *ACS Appl. Mater. Interfaces*, 2017, **9**, 23555.
- 4 L. Chen, X. Zhou, W. Nie, Q. Zhang, W. Wang, Y. Zhang and C. He, *ACS Appl. Mater. Interfaces*, 2016, **8**, 33829.
- 5 B. Lei, M. Wang, Z. Jiang, W. Qi, R. Su and Z. He, *ACS Appl. Mater. Interfaces*, 2018, **10**, 16698.
- 6 Y. Yang, Q. Hu, Q. Zhang, K. Jiang, W. Lin, Y. Yang, Y. Cui and G. Qian, *Mol. Pharm.*, 2016, **13**, 2782-2786.
- 7 W. Lin, Q. Hu, K. Jiang, Y. Yang, Y. Yang, Y. Cui and G. Qian, *J Solid State Chem*, 2016, **237**, 307.
- 8 X. Gao, M. Zhai, W. Guan, J. Liu, Z. Liu and A. Damirin, *Acs Appl Mater Interfaces*, 2017, **9**, 3455.